• Progressing key technical milestones towards building and demonstrating a quantum qubit device
• Completing first phase of Quantum Machine Learning models for fraud detection
• Creating an alpha-prototype of the blood potassium Biochip at clinical standard

Archer Materials Limited, a quantum technology company, has provided its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2026. The company has made progress across its key technology platforms, including quantum computing, sensing, and medical diagnostics. In the quantum computing space, the team has been working on building devices for testing to demonstrate progress on qubit readout, a critical component for the qubit. They have also been scaling up carbon material growth for device fabrication at wafer scale. Archer's partnership with Emergence Quantum is also progressing, with the teams mapping graphene across multiple quantum domains and preparing pathways for development. In the sensing domain, the collaboration with the Swiss Federal Technology Institute of Lausanne has been active, with the team growing carbon film and building test devices for electrical detection of magnetic resonance. Archer's Quantum Machine Learning (QML) initiative has completed its first stage, involving the selection of a dataset and the application of data reduction techniques to enable QML simulations and benchmarking. The company expects to have a full QML prototype ready by the end of 2026. In the medical diagnostics space, Archer has built an alpha-prototype of its blood potassium Biochip, which demonstrated potassium measurement accuracy within ±0.3 mM in blood samples, validating the device under Clinical Laboratory Improvement Amendments (CLIA) requirements. The company is set to complete the beta-prototype of the Biochip later this year, which will be used in clinical trials and serve as the foundation for discussions with major MedTech corporations. Archer maintains a strong cash position of $10.3 million and no debt to fund its R&D and commercial activities.

Archer remains focused on accelerating multiple pathways to commercialisation for its suite of quantum technologies, which will open opportunities to drive long-term value creation. The company is set to complete the beta-prototype of the Biochip later this year, ahead of clinical trials and commercial negotiations.